|
RLMD | Relmada Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.08 |
| Leverage | 36.37% |
| Market Cap | $ 122.2m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -56.1m |
| Margin | -3349.46% |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the United States. The company is headquartered in New York, New York.